Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 16;60(11):1876.
doi: 10.3390/medicina60111876.

Porokeratoses-A Rare Group of Dermatoses

Affiliations
Review

Porokeratoses-A Rare Group of Dermatoses

Agnieszka Anderska et al. Medicina (Kaunas). .

Abstract

Porokeratoses represent a rare group of skin diseases characterized by abnormal keratinization. The condition may have a genetic background and can be triggered by environmental factors, including UV exposure and infections. Several clinical variants of porokeratosis can be distinguished, including Mibelli's porokeratosis, disseminated superficial actinic porokeratosis, superficial disseminated porokeratosis, and porokeratosis palmaris plantaris et disseminata. Diagnosis is established based on clinical and histopathological examination, dermatoscopy, and reflectance confocal microscopy. Various treatment options are available, including topical combination therapy with cholesterol and statins, topical retinoids, cryotherapy, laser therapy, and surgical excision of lesions, but none are fully effective. The success of these treatments can vary significantly based on the specific type of porokeratosis and individual patient characteristics, with many outcomes falling short of expectations. Since the disease is considered a precancerous condition, patients with porokeratosis should remain under regular dermatological control.

Keywords: abnormal keratinization; malignant transformation; porokeratoses.

PubMed Disclaimer

Conflict of interest statement

A.A., A.K.-S. and E.M. have nothing to declare. A.R. has worked as a consultant or speaker for AbbVie, Bioderma, Celgene, Chema Elektromet, Eli Lilly, Galderma, Janssen, Leo Pharma, Medac, Menlo Therapeutics, Novartis, Pierre-Fabre, Sandoz, and Trevi and participated as a principal investigator or sub-investigator in clinical trials sponsored by AbbVie, Arcutis, Drug Delivery Solutions Ltd., Galderma, Genentech, Janssen, Kymab Limited, Leo Pharma, Menlo Therapeutics, MetrioPharm, MSD, Novartis, Pfizer, and Trevi.

Figures

Figure 1
Figure 1
Histopathological features of disseminated superficial actinic porokeratosis (DSAP) include the presence of a cornoid lamella, epidermal atrophy, and lymphocytic infiltration in the dermis. The mevalonate pathway, responsible for cholesterol biosynthesis, is linked to the pathogenesis of porokeratosis.
Figure 2
Figure 2
(A) Disseminated superficial actinic porokeratosis (DSAP): diffuse, small plaques on the man’s forearm. (B) Dermatoscopic view—a peripheral white line with a doubled edge, characteristic of porokeratosis (black arrow).
Figure 3
Figure 3
(A) Porokeratosis of Mibelli—two plaques on the man’s arm and forearm. (B)Dermatoscopic view: characteristic peripheral white-yellow line with a doubled edge (black arrow) and multiple dot-type vessels.
Figure 4
Figure 4
(A) Disseminated superficial porokeratosis—multiple small erythematous plaques on the woman’s back. (B) Dermatoscopic view—a peripheral, interspersed white line with a doubled edge and centrally located linear vessels and single keratotic plug at the openings of hair follicles (black arrow).
Figure 5
Figure 5
(AC) Porokeratosis palmaris, plantaris et disseminata: multiple small plaques on the woman’s hands and feet. (BD) Dermatoscopic view—peripheral white lines with a doubled edge (black arrow) with a central structureless area, characteristic of porokeratosis.

References

    1. Pietkiewicz P., Korecka K., Salwowska N., Kohut I., Adhikari A., Bowszyc-Dmochowska M., Pogorzelska-Antkowiak A., Navarrete-Dechent C. Porokeratoses—A Comprehensive Review on the Genetics and Metabolomics, Imaging Methods and Management of Common Clinical Variants. Metabolites. 2023;13:1176. doi: 10.3390/metabo13121176. - DOI - PMC - PubMed
    1. Bhaskar S., Jaiswal A., Raj N., Reddy D. Porokeratosis-Head to Toe: An Unusual Presentation. Indian Dermatol. Online J. 2015;6:101. doi: 10.4103/2229-5178.153012. - DOI - PMC - PubMed
    1. Arranz-Salas I., Sanz-Trelles A., Ojeda D.B. P53 Alterations in Porokeratosis. J. Cutan. Pathol. 2003;30:455–458. doi: 10.1034/j.1600-0560.2003.00097.x. - DOI - PubMed
    1. Novice T., Nakamura M., Helfrich Y. The Malignancy Potential of Porokeratosis: A Single-Center Retrospective Study. Cureus. 2021;13:e13083. doi: 10.7759/cureus.13083. - DOI - PMC - PubMed
    1. Maubec E., Duvillard P., Margulis A., Bachollet B., Degois G., Avril M. Common Skin Cancers in Porokeratosis. Br. J. Dermatol. 2005;152:1389–1391. doi: 10.1111/j.1365-2133.2005.06639.x. - DOI - PubMed

LinkOut - more resources